Enanta Pharmaceuticals (NASDAQ:ENTA) Releases Earnings Results, Misses Estimates By $0.16 EPS

Enanta Pharmaceuticals (NASDAQ:ENTA) announced its quarterly earnings data on Monday. The biotechnology company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.16), Zacks reports. The firm had revenue of $14.36 million during the quarter, compared to the consensus estimate of $16.76 million. Enanta Pharmaceuticals had a negative net margin of 89.56% and a negative return on equity of 64.04%.

Enanta Pharmaceuticals Stock Up 0.3%

Shares of NASDAQ:ENTA opened at $13.81 on Tuesday. Enanta Pharmaceuticals has a 12-month low of $6.45 and a 12-month high of $17.15. The business has a 50 day moving average of $13.11 and a 200-day moving average of $13.43. The stock has a market cap of $401.57 million, a PE ratio of -5.33 and a beta of 0.98.

Institutional Trading of Enanta Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC boosted its stake in Enanta Pharmaceuticals by 674.7% in the 1st quarter. AQR Capital Management LLC now owns 357,109 shares of the biotechnology company’s stock valued at $1,971,000 after purchasing an additional 311,010 shares during the period. Millennium Management LLC lifted its holdings in shares of Enanta Pharmaceuticals by 50.2% during the first quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company’s stock worth $7,435,000 after buying an additional 449,945 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Enanta Pharmaceuticals by 5.3% during the first quarter. Goldman Sachs Group Inc. now owns 130,410 shares of the biotechnology company’s stock worth $720,000 after buying an additional 6,549 shares in the last quarter. Invesco Ltd. boosted its position in shares of Enanta Pharmaceuticals by 4.3% in the second quarter. Invesco Ltd. now owns 62,884 shares of the biotechnology company’s stock valued at $475,000 after acquiring an additional 2,607 shares during the period. Finally, Marshall Wace LLP boosted its position in shares of Enanta Pharmaceuticals by 0.8% in the second quarter. Marshall Wace LLP now owns 857,412 shares of the biotechnology company’s stock valued at $6,482,000 after acquiring an additional 6,522 shares during the period. 94.99% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on ENTA shares. Wall Street Zen downgraded shares of Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, May 31st. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Enanta Pharmaceuticals in a research report on Tuesday, June 23rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Friday, July 17th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $20.29.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.